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The topic of this panel was suggested by Dr. Richard C. Boronow, the president 
presiding over the 1979 meeting of the Society of Gynecologic Oncologists, and 
Dr. Morrow. Fairly rigid criteria were drawn up (Table 1) and mailed to over 40 
members of the society soliciting individuals or institutions with a large experi- 
ence who would be willing to participate. From the 20 replies the three largest 
series receiving adjuvant radiation therapy (RT) and the three largest observation 
(no radiation therapy) series were selected. In each collective group it was esti- 
mated that approximately 100 patients with pelvic node metastasis would be 
represented with a minimum follow-up of 2 years. The actual number of cases was 
much smaller than estimated in the RT group and greater in the observation group 
resulting in a rather large imbalance (Table 2). 
The panelists were given prepared data forms to complete by filling in numbers 
and the institutional name in order to standardize the data as much as possible. 
These tables also were to be used as slides to accompany each subseries as it was 
presented at the meeting. The data from all series were collated and presented by 
1 Author of text. 
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TABLE 1 
CRITERIA FOR PANELISTS SERIES 
1. All cases must be FIG0 Stage Ib. 
2. Squamous cell carcinoma. 
3. No treatment prior to surgery including preoperative radiation. 
4. Histologically confirmed pelvic node metastasis with no macroscopic residual disease. 
5. Minimum follow-up of 2 years; 5 years preferred. 
6. In the RT series, radiation must be initiated within 2 months postoperatively. 
7. All cases treated by abdominal radical hysterectomy and bilateral pelvic lymphadenectomy. 
8. Contemporary series, personal preferred. 
9. Surgical-pathological data available. 
10. Details of radiation therapy available. 
11. Information regarding follow-up and complications. 
12. Information on time and site of recurrence. 
TABLE 2 
STAGE Ib SQUAMOUS CELL CARCINOMA OF THE CERVIX WITH PELVIC NODE METASTASIS 
Radiation therapy Total 
series cases 
Girtanner and Averette 27 
Austin and Shingleton 14 
Webb 8 
Total 49 






the panel moderator following the individual series. The discussion was initiated 
by Drs. Howard Welder and Hugh R. K. Barber and then opened to the floor. 
Results. Table 3 presents the survival at 2 years for both treatment groups. 
There was a marked drop in survival for the observation group when more than 
three nodes were involved by metastases. Information on bilaterality was not 
obtained. There is a suggestion that adjuvant radiation therapy enhances survival 
in patients with multiple positive nodes, but there was no measurable benefit to 
patients with three or fewer node metastases. The 5-year survival rates for both 
TABLE 3 
STAGE Ib SQUAMOUS CELL CARCINOMA OF THE CERVIX WITH PELVIC NODE METASTASES 
COLLATED RESULTS 
SURVIVAL AT 2 YEARS 
RT” No RT 
No. nodes NED/Total % NED/Total % 
1 11121 52 3 1142 74 
2-3 13/18 72 46l60 77 
4-S O/l 0 9125 36 
>5 719 78 9/19 47 
Total 31149 63 951146 65 
a NED, No evidence of disease; RT, radiation therapy. 
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TABLE 4 
STAGE Ib SQUAMOUSCELLCARCINOMAOFTHECERVIX WITHPELVICNODEMETASTASES 
COLLATED SERIES 
SURVIVAL AT 5 YEARS 
No. nodes 
positive 
RT No RT 
NED/Total % NEDiTotal % 
1 7114 50 29142 69 
2-3 619 67 41158 71 
4-5 O/l 0 8125 32 
>5 516 83 J/19 37 
Total 18130 60 851144 59 
groups are presented in Table 4. These data concur with the often reported 5-year 
survival rates of 50% and the notion that most recurrences appear within the first 2 
years after treatment. 
The sites of recurrence are given in Table 5. It is interesting that while the 
recurrence percentage is almost identical in both groups, 9 of 18 recurrences (50%) 
in the RT groups were pelvic while 48/57 (84%) were pelvic in the no RT group. 
(Onsrud [l] noted a similar pattern of recurrence relative to therapy in a ran- 
domized series of patients with Stage I endometriai carcinoma.) The lesional size 
was similar in the two groups. No explanation is apparent for the earlier recur- 
rence time of the RT cases with pelvic disease only. 
The incidence of major complications was tabulated for each treatment group 
(Table 6). Based on these small numbers the data are consistent with the general 
TABLE 5 





Lesion size (cm) 
RT No RT 
Recurrence 
time (months) 
RT No RT 
Total (% all Total (% all average average average average 
N cases) N cases) @we) box& (range) (range) 
Pelvis 5 a.2 27 18.5 
C 3 6.1 8 5.5 3 
(2-4) 
PW 2 4.1 19 13.0 3.5 
(2-5) 
DM 9 18.4 9 6.2 4 
(1.5-6) 
Both 4 8.2 21 14.4 4.9 
(3.5-5.5) 
Unknown 2 4.1 - - - 



































a Only 30 cases followed 5 years or more. 
b All cases followed 5 years or more. 
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TABLE 7 
STAGE Ib SQUAMOUS CELL CARCINOMA OF THE CERVIX WITH PELVIC NODE METASTASIS 










Percentage of all 
complications 
< 4500 rad WP 7 14 2 33 
4500-5500 rad WP 27 55 1 17 
> 5500 rad WP 14 28 3 50 
Not stated 1 2 0 0.0 
Total 49 100 6 100 
n WP, Whole pelvis. 
experience that radiation therapy after radical surgery bears the risk of increased 
complications. Those occurring after RT required operative intervention more 
frequently. There were no treatment deaths reported among these 195 patients. 
The overall ureteral fistula rate was 3.1% (6/195). In the RT group an analysis of 
the complications was done to correlate risk with radiation dose (Table 7). All 
cases received external beam RT without intracavitary brachytherapy. Patients 
receiving 5500 rad whole pelvis or more accounted for 28% of all cases and 50% 
of the complications, a suggestion that the expected increase in risk with more 
intense radiation did occur. 
Comment. A literature review was undertaken for purposes of comparison and 
also to see if the already reported data justified the widespread opinion among 
radiation therapists and gynecologic oncologists that pelvic node metastasis was 
an established indication for pelvic radiation after radical hysterectomy in women 
with Stage Ib squamous carcinoma of the cervix. Over 30 articles reporting results 
of surgery in early cervix cancer were reviewed. Of these, six (only three from the 
United States) were evaluable as judged by the following criteria: (1) published 
within the last 10 years; (2) Stage Ib cases only; (3) no preop pelvic (external) 
radiation; (4) survival rate at 2 to 5 years post-therapy for cases with node 
metastases; (5) survival reported for cases receiving postoperative adjuvant pelvic 
RT or no further treatment. The 5-year survival for the RT and no RT series are 
presented in Tables 8 and 9, respectively. The overall differences are not statisti- 
cally significant (0.1 > p > 0.05 by the x2 method). Except for the report from 
TABLE 8 
LITERATURE REVIEW 
STABE Ib CERVICAL CARCINOMA POSTOPERATIVE RT 
Author Year 




Kelsor” 1973 14 57 
Rampone131 1973 81 63 
Masubuchi@J 1%9 14 57 
Total 109 61.5 
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TABLE 9 
LITERATURE REVIEW 
STAGE Ib CERVICAL CARCINOMA 






Pive+ 1975 39 55.2 
H&6’ 1972 37 40.5 
Burchtrl 1970 23 56.0 
Total 99 50.0 
Taiwan [6] the results in the selected literature review are virtually the same as the 
results reported by this panel. No conclusions can be drawn regarding the efficacy 
of adjuvant pelvic radiation therapy in this clinical setting either from the literature 
or the panel data. 
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